This has put executives and business owners in the very uncomfortable position of needing to make medical judgments about their staff, or be seen as taking punitive measures that could affect overall morale
Clin Psychol Rev (2020) 77:101830
Currently, both peptides are approved for MACE reduction based on the following data: The effectiveness of semaglutide for reducing MACE risk was studied in the SUSTAIN-6 trial, which included a total of 3297 diabetics, the majority of which had cardiovascular risks
Use of GLP-1 drugs is highest among adults who report being diagnosed with conditions these drugs are prescribed to treat, including those who have ever been told by a doctor that they have diabetes (57% ever used, including 45% currently using), heart disease (40% ever, 29% currently), and those that have been told by a doctor that they are overweight or obese in the past five years (34% ever, 23% currently)
Detailed Results 1 From January 1, 2022, to June 30, 2025, GLP-1 exposure was defined as first prescription prior to the breast imaging examination with documented outcome from the imaging